Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Emerging Non-transplant-based Strategies in Treating Pediatric Non-Hodgkin’s Lymphoma

Emerging Non-transplant-based Strategies in Treating Pediatric Non-Hodgkin’s Lymphoma Lymphomas represent the third most common cancer in children and adolescents. The non-Hodgkin’s lymphomas comprise a heterogeneous group of tumors, with distinct clinical and pathologic features. Although intensive multi-agent chemotherapy has made non-Hodgkin’s lymphoma one of the most curable malignancies in children and young adults, there is room for improvement in treatment, particularly for those with advanced-stage disease and those who relapse after conventional therapy. New approaches are now attempting to reduce the burden of treatment, to focus on novel and more specific biologic targets, and to improve outcomes for patients with advanced-stage disease while reducing the potential for late effects. A comprehensive review of all potential agents is beyond the scope of this review, which will focus on some of the newer strategies for treating non-Hodgkin’s lymphoma that are coming into clinical use today. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Hematologic Malignancy Reports Springer Journals

Emerging Non-transplant-based Strategies in Treating Pediatric Non-Hodgkin’s Lymphoma

Loading next page...
 
/lp/springer-journals/emerging-non-transplant-based-strategies-in-treating-pediatric-non-7iiQHrTI07

References (68)

Publisher
Springer Journals
Copyright
Copyright © 2010 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Hematology
ISSN
1558-8211
eISSN
1558-822X
DOI
10.1007/s11899-010-0058-6
pmid
20640605
Publisher site
See Article on Publisher Site

Abstract

Lymphomas represent the third most common cancer in children and adolescents. The non-Hodgkin’s lymphomas comprise a heterogeneous group of tumors, with distinct clinical and pathologic features. Although intensive multi-agent chemotherapy has made non-Hodgkin’s lymphoma one of the most curable malignancies in children and young adults, there is room for improvement in treatment, particularly for those with advanced-stage disease and those who relapse after conventional therapy. New approaches are now attempting to reduce the burden of treatment, to focus on novel and more specific biologic targets, and to improve outcomes for patients with advanced-stage disease while reducing the potential for late effects. A comprehensive review of all potential agents is beyond the scope of this review, which will focus on some of the newer strategies for treating non-Hodgkin’s lymphoma that are coming into clinical use today.

Journal

Current Hematologic Malignancy ReportsSpringer Journals

Published: Jul 17, 2010

There are no references for this article.